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Contingent valuation: what needs to be done?
RICHARD D. SMITH*
Health Policy Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine,
London, UK
TRACEY H. SACH
School of Chemical Sciences and Pharmacy and Health Economics Group, University of East Anglia, Norwich, UK
Abstract : Contingent valuation (CV) has been argued to have theoretical
advantages over other approaches for benefit valuation used by health
economists. Yet, in reality, the technique appears not to have realised these
advantages when applied to health-care issues, such that its influence in
decision-making at national levels has been non-existent within the health
sector. This is not a result of a lack of methodological work in the area, which
has continued to flourish. Rather, it is a result of such activities being
undertaken in a rather uncoordinated and unsystematic fashion, leading CV to
be akin to a ‘ship without a sail’. This paper utilises a systematic review of the
CV literature in health to illustrate some important points concerning the
conduct of CV studies, before providing a comment on what the remaining
policy and research priorities are for the technique, and proposing a guideline
for such studies. It is hoped that this will initiate some wider and rigorous
debate on the future of the CV technique in order to make it seaworthy, give
it direction and provide the right momentum.
Contingent valuation: a ship without a sail?
Contingent valuation (CV) provides a survey-based method for estimating the
monetary benefits of non-marketed goods and services (see Mitchell and Carson
(1989) and Bateman et al. (2002) for fuller description of the method). Although
CV has been applied in the environmental and transport literature since the
early 1960s, and was applied in the health area in the mid 1970s (Acton, 1973,
1976), it remained neglected by health economists until the late 1980s and early
1990s (see Diener et al. (1998), Klose (1999) and Olsen and Smith (2001)).
Since that time, the number of CV studies in health care has increased rapidly
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(see Diener et al. (1998), Klose (1999), Olsen and Smith (2001), Smith (2003)
and Sach et al. (2007)), covering a wide variety of disease areas and countries;
although this number remains small compared to the number of cost-effectiveness
and cost–utility studies conducted over the same period (for instance, the OHE
(Office of Health Economics) Health Economic Evaluation Database holds
35,000 plus references (http://www.ohe-heed.com/)).
Using data from a CV database compiled by the authors following on-going
systematic reviews of the literature, the methods of which have been described
extensively elsewhere (Olsen and Smith, 2001; Smith, 2003; Sach et al., 2007),
Figure 1 illustrates that in the 5 years, from 2001 to 2005, 163 CV studies
were published.
Table 1 shows that the USA and UK remain the largest producers of CV
studies in health care (Sweden contributed a number of studies during the 1990s,
but activity has declined recently). However, the most obvious change in the last
few years has been the application of CV in countries other than the USA, UK,
Canada and Sweden (the main, or only, players in the 1980s and 1990s). From
2000, at least one CV study in health care had been conducted in 35 other
countries. CV thus appears to be making inroads in a number of different health
systems and cultures, and especially so in some developing countries where often
these studies are used to estimate possible demand and co-payment rates, and
thus have a very specific policy focus.
Table 2 shows that many of the early studies were focussed on cardiovascular
disease – predominantly by Johannesson in Sweden – but the wider geographical
use of CV illustrated above coincides with a broadening of clinical area from
the mid-1990s.
Table 3 shows that a significant, but nonetheless a minority, of interventions
evaluated have been pharmaceutical products. However, since 2000, there have
been more studies focussed on screening for various diseases – perhaps because a
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Figure 1. Number of CV studies per year (1985–2005)
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significant component part of screening concerns the value of information, not
usually captured in other evaluation methods.
It can be seen, therefore, that there has been an expansion in total number,
breadth of geographical coverage (and hence health systems and cultures),
clinical areas, and interventions. The popularity of CV thus shows no signs of
abatement – indeed, quite the opposite – and this makes it timely to critically
review the development of CV and raise future research directions.
Despite the technique’s growing popularity, there remain a number of critical
unresolved issues. These may be categorised as concerning: (i) whether or not
there are (or could be) substantial advantages to the use of the technique over
alternative outcome measurement strategies; and (ii) the appropriate metho-
dology for conducting CV generally, and in its application in health economics
more specifically (Cookson, 2003; Hanley et al., 2003).
Numerous specific CV research questions could be raised as important in a
paper such as this. For instance, what the ‘threshold’ income level is for
impacting on sensitivity, the impact of prominent numbers on valuations for a
wide range of goods, and the impact of response acquiescence or ‘yeah-saying’.
These have been considered in more detail, including by the authors, elsewhere
(e.g. Smith, 2001, 2004, 2005, 2007a, 2007b, 2008; Yeung et al., 2003, 2006;
Table 1. Country of origin by year
Year UK USA Canada Sweden Other Total
1985 0 2 0 0 0 2
1986 0 1 0 0 0 1
1987 0 1 0 0 1 2
1988 1 2 0 0 0 3
1989 0 0 0 0 0 0
1990 0 2 1 0 0 3
1991 0 1 1 2 0 4
1992 1 1 0 1 0 3
1993 0 1 0 2 1 4
1994 0 4 1 1 3 9
1995 1 1 2 1 0 5
1996 1 1 0 3 2 7
1997 6 3 0 2 0 11
1998 3 10 0 2 3 18
1999 1 4 0 0 2 7
2000 3 9 2 1 8 23
2001 5 14 1 1 4 25
2002 7 8 2 0 14 31
2003 7 8 5 0 12 32
2004 8 11 1 1 16 37
2005 0 11 7 0 20 38
Total 44 95 23 17 86 265
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Covey and Smith, 2006; Whynes et al., 2007). However, focus on such questions,
important as they may be for methodological advancement, would miss more
significant and fundamental issues facing the technique. The discussion contained in
this paper therefore invites health economists to consider: (i) whether there is a role
for CV in health economics; and (ii), if yes (or perhaps a weaker not sure), how can
CV development progress to a stage to realise the desired potential, in light of
developments over the last 20 years of research in the area?
At present, we would suggest that CV is like a ship without a sail – it is adrift
in the sea of economic evaluation methodologies, unsure of a direction and
without the ability to move in a purposeful manner to achieve its destination.
Throughout the paper the metaphor of the ship is used, since for a boat to float
it first needs to be built correctly, which requires an in depth understanding of
the dynamics and dimensions of a successful boat; that all components are
present to make it move; and that once moving, an experienced captain oversees
the direction and speed of travel. This is a useful metaphor for CV because
uncertainties remain about the exact dynamics and dimensions of the technique,
Table 2. Clinical area/diagnosis over time
Year Cardiovascular Cancer
Obstetrics and
gynecology Infection
Mental
illness Arthritis Other* Total
1985 0 0 0 0 0 0 2 2
1986 0 0 0 0 0 1 0 1
1987 0 0 1 0 0 0 1 2
1988 1 0 0 0 0 0 2 3
1989 0 0 0 0 0 0 0 0
1990 0 0 0 0 0 0 3 3
1991 2 0 0 0 0 0 2 4
1992 1 0 0 0 0 0 2 3
1993 3 0 0 0 0 0 1 4
1994 1 0 2 1 0 0 5 9
1995 0 0 2 0 1 0 2 5
1996 2 0 1 1 0 0 3 7
1997 1 0 3 0 0 0 7 11
1998 0 1 3 4 0 1 9 18
1999 0 0 0 1 1 0 5 7
2000 0 2 1 4 0 2 14 23
2001 2 5 1 6 2 0 9 25
2002 1 1 0 12 1 1 15 31
2003 2 5 0 5 3 1 16 32
2004 2 4 2 6 0 2 21 37
2005 0 5 0 13 2 1 17 38
Total 18 23 16 53 10 9 136 265
*Other includes, for example, different locations for care, irradiation of food, asthma and respiratory
illness, blood products, and information from pharmacists on medicine use.
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and earlier research has proceeded in a rather ad hoc and uncoordinated manner
that has resulted in the technique having limited influence in decision-making in
health care.
Is CV seaworthy?
The first major question to ask is whether the good ship CV is ready to be taken
to the sea. Is the technique worth further research, time, and money being
invested into it so that it can form part of the health economists’ toolkit? This
depends on whether there is a realisable advantage to using CV over other
techniques. If the answer to this question is no then CV should be abandoned as
unseaworthy, and efforts put in to developing other ships.
In this respect, Olsen and Smith (2001) advanced three arguments why CV
may offer real advantage over other outcome measures. These included its
foundations in welfare economics, that it does not restrict outcomes assessed to
health outcomes only, and that monetary valuation of benefits and costs is
required for decisions about allocative efficiency (that is, it allows a full cost–benefit
Table 3. Intervention by year
Year Drug Surgery Screening Other* Total
1985 0 0 0 2 2
1986 1 0 0 0 1
1987 0 0 0 2 2
1988 0 0 2 1 3
1989 0 0 0 0 0
1990 0 0 0 3 3
1991 3 0 0 1 4
1992 1 0 0 2 3
1993 2 0 0 2 4
1994 1 0 0 8 9
1995 1 1 1 2 5
1996 2 0 0 5 7
1997 1 1 2 7 11
1998 8 0 1 9 18
1999 1 0 2 4 7
2000 6 3 4 10 23
2001 7 1 5 12 25
2002 15 0 3 13 31
2003 8 1 4 19 32
2004 10 2 3 22 37
2005 20 1 1 16 38
Total 87 10 28 140 265
*Other includes, for example, information provisions, unspecified movement between health states, and
irradiation.
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analysis (CBA) to be undertaken). The first of these arguments was largely
refuted as unimportant on the basis that it is more important for a method to fit
with societal value judgements, which may be expected to differ across countries
and health systems. For instance, one could argue that the failure by the
National Institute for Health and Clinical Excellence (NICE), in the UK, to
adopt CV as an approach in its methods manual is one indication that UK
society does not share the values of CV within health care (NICE, 2004). That
this may reflect the situation that health care is free at the point of use, does not
seem a logical argument since NICE still has to make a decision about societal
willingness to pay for a quality-adjusted life year (QALY; as discussed below);
although, removing this judgement from the individual level may in some way
make it appear more acceptable.
In terms of the second argument, Olsen and Smith (2001) categorised the
benefits measured by CV as: health outcomes, where three dimensions were
identified including change in health state, duration, and probability (which are
those assessed by the QALY); process utility, which may also derive from the use
of health care; and non-health outcomes, covering option value and caring
externalities. Their review however, found that, in practice, few studies made
use of this potential advantage, mainly through poor scenario specification.
In respect of the third argument in favour of CV – that it can inform allocative
efficiency decisions through application in CBA – Olsen and Smith (2001) found
that most studies reviewed were partial evaluations, valuing one programme
alone. Together with the fact that most also did not compare CV values to the
cost of the programmes, this suggests that few CV studies were making use of
their theoretical advantage. Such was the evidence back in 2001, that Olsen and
Smith had ‘the distinct feeling of a huge mismatch between the theoretical glory
of WTP and the usefulness for public health policy of the majority of surveys
which have applied this method’ (Olsen and Smith, 2001: 47). Updating this
review to see if there has been a change over time finds that the same conclusion
can largely be reaffirmed.
Looking first at health outcomes, one can see from Table 4 that the majority of
studies do not explicitly address the valuation of health outcomes comprehensively.
Table 4 also suggests that this situation has not improved, although there are fewer
who provide no details, as a proportion, or for whom health is not the focus.
Table 5 provides a breakdown of non-outcome attributes or ‘process utility’,
and provides a comparison between the two time periods.
In terms of non-current use attributes – reflecting option value and extern-
alities – a more complex picture of the interaction between the scenario speci-
fication and the respondent arises. That is, which values are activated in
this respect depends upon the role in which respondents are placed. To assess
the extent to which CV studies had actually sought to include these elements
of value, each study was examined for three types of respondents: users,
convenience sample, and the general population. Users are most often patients,
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but sometimes their relatives. Convenience samples are most often groups of
students or seminar participants. General population samples are those who are
supposed to be representative of the population. Table 6 shows that most sur-
veys included only use-value, reflecting the fact that most surveys asked patients
only. Only 24% of studies have asked the general population. When users may
have expressed option value or externalities, this refers to preventive pro-
grammes. Table 6 also illustrates that this picture has changed little over the two
time periods considered.
Given that CV studies in health care are overwhelmingly constructed to elicit
use-value alone, the question that arises therefore is whether CV studies in
health care are misspecified. Empirical research suggests that, if these results
are more widely replicable, most CV studies in health care may indeed be
misspecified, as a significant element of the value of the good in question is not
Table 4. Health outcomes description
No. of studies
Dimension 1985–1998 1999–2005 1985–2005
Not the focus 19 16 35
None 19 50 69
Health status 6 66 72
Probability 10 29 39
Health status and duration 5 5 10
Health status and probability 4 21 25
Duration and probability 1 0 1
Health status, duration and probability 7 7 14
Total 71 194 265
Table 5. Non-outcome descriptions
No. of studies
Dimension 1985–1998 1999–2005 1985–2005
Not the focus 23 82 105
Not provided 7 58 65
Information 10 20 30
Caring 5 25 30
Other 13 13 26
Information and caring 1 5 6
Caring and other 2 0 2
Information and caring and other 1 0 1
Total 71 194 265
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being captured (Smith, 2007). This is important as, ultimately, the cost–benefit
calculus and policy recommendation would be biased against the good in
question, and in a comparison between goods. Of course, whether studies
actually are misspecified depends upon the policy context within which the CV
study is conducted. For instance, it may be argued that the most appropriate
policy context is often one that is ex ante, and thus that the only source of
relevant value is option value.
Updating the contribution that CV can make to CBA and allocative efficiency
decisions reveals that in terms of the number of partial evaluations (163 or 62%
of studies) this does seem to have improved slightly over time, but the number
comparing CV values to the cost of interventions was not much higher (29
studies). The challenge here is that, given the failure of CV to achieve its
Table 6. Types of values by type of respondents
Use value
Option
value Externalities
Option and
externalities Total
Users
1985–1999 42 2 1 1 46
1999–2005 68 18 9 12 107
Total 110 20 10 13 153
Convenience sample
1985–1999 8 2 0 2 12
1999–2005 23 0 0 1 24
Total 31 2 0 3 36
General population
1985–1999 5 1 0 3 9
1999–2005 41 7 2 4 54
Total 46 8 2 7 63
Users and convenience sample
1985–1999 0 1 0 0 1
1999–2005 5 1 1 0 7
Total 5 2 1 0 8
Users and general population
1985–1999 0 0 0 1 1
1999–2005 0 3 0 1 3
Total 0 3 0 1 4
Convenience and general population
1985–1999 1 0 0 0 1
1999–2005 0 0 0 0 0
Total 1 0 0 0 1
Total
1985–1999 56 6 2 7 71
1999–2005 137 29 11 17 194
Total 193 35 13 24 265
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theoretical advantages, can other outcome approaches devise ways to incorpo-
rate these advantages. If they can then clearly CV might become redundant.
Of course, one possible alternative to conducting individual CV studies is to
maintain the current practice of conducting cost–utility analysis (CUA), but
have a ‘translation’ factor to convert these in to CBA through use of a statistic or
formula representing social willingness-to-pay (WTP) for a QALY (Adler, 2006;
Gafni and Birch, 2006). Without such a ‘translation’ factor, there is no way in
which the cost effectiveness of health interventions can be compared with that of
interventions in other sectors, such that an inefficient allocation across sectors is
a distinct possibility (noting that, of course, even if such a translation factor
were used, basing this on a QALY would still only represent the WTP for health
benefits, thus still excluding some of the claimed advantages of CV over other
techniques).
Currently, bodies such as NICE, have to make an implicit judgement about
whether the QALY gains are ‘worth’ what they will cost (Devlin and Parkin,
2004). However, the ‘threshold’ values adopted (such as £20,000–£30,000 per
QALYabove or below which a new therapy will be rejected or recommended for
adoption in England and Wales, and the commonly-mentioned h18,000 in the
Netherlands) are more or less ‘arbitrary’ (NICE, 2004; Rawlins and Culyer,
2004), and NICE has recently funded work looking at the assessment of a
money value (Devlin and Parkin, 2004). Similar work is being undertaken
elsewhere, for instance, Australia (George et al., 2001). There are also a growing
number of papers that have either explicitly called for, or at least implied the
need for, estimates of the monetary value of a QALY, with empirical estimates
ranging from around £1,000 to over £500,000 per QALY, depending on
assumptions used and whether values have been imputed from the value of a
prevented fatality or a specific survey looking at WTP for changes in health
states (Phelps and Mushlin, 1991; Johannesson, 1995; Garber and Phelps, 1997;
Johnson et al., 1997; Bleichrodt and Quiggin, 1999; Hirth et al., 2000; Dolan
and Edlin, 2002; Hammitt, 2002; Gyrd-Hansen, 2003; Devlin and Parkin,
2004; Eichler et al., 2004; Buxton, 2005; Byrne et al., 2005; Franica et al., 2005;
King et al., 2005; Haninger and Hammitt, 2006; Adler, 2006; Van Houtven
et al., 2006).
However, although such a calculation is appealing, and interest in generating
such a value increasing, it is not as straightforward as it initially appears and
there are a range of issues that need to be considered when applying WTP at a
societal level. These have been considered in depth elsewhere (Richardson and
Smith, 2004; Smith and Richardson, 2005), but in brief concern whether the
sum of individual WTP equals social WTP, whether individual WTP maps
directly into social WTP, whether personal income is the appropriate budget
constraint, and whether WTP should be adjusted for ability to pay. The degree
to which these considerations can be overcome will determine the degree to
which CV may be unnecessary. The recently completed SVQ (Social Value of a
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QALY) project in the UK has considered a number of these issues (Donaldson
et al., 2003) and will be extended, on a European level, through the EuroVaQ
(European Value of a QALY) project (Donaldson et al., 2006). These projects
are designed to provide information concerning whether the values/weights
attached to gains in quality and length of life should vary according to the
characteristics of the patients receiving them, and how much the health system
should be spending (at the margin) to achieve such gains. This involves testing
alternative procedures in order to: (i) determine whether it is feasible to derive
a baseline value of a QALY sufficiently robust to be of use to decision makers;
(ii) explore the issues involved in incorporating ‘citizen’ concerns into a WTP
framework; and (iii) identify which method(s) (if any) appear to be the most
promising candidate(s) for national decision-making (and, in EuroVaQ, look at
cross-country differences).
Of course, despite all this effort, whether a ‘social value of a QALY’ is
obtainable, or even desirable, is a moot point. It could simply be that economists
are trying to combine conceptually incomparable measures – that the conditions
for equivalence are excessively restrictive and unrealistic (e.g. Dolan and Edlin,
2002). Given that we are almost certainly looking for a non-linear function,
rather than a universal constant, WTP for money value of a QALY, it might well
be that in trying to value a QALY we simply support the replacement of the
QALY with WTP, and thus the replacement of CUA with CBA (Van Houtven
et al., 2006).
Therefore, if a ‘social value of a QALY’ is not feasible, or perhaps desirable,
then we are left in the position of having to address the issues discussed in this
and previous reviews of CV (Diener et al., 1998; Klose, 1999; Olsen and Smith,
2001, Smith 2003, Sach et al., 2007). In this respect, the need for a coordinated
research effort and the specification of some form of reference case and/or
guidelines for conduct of CV in health economics appears unavoidable, and
perhaps even more important. That is, if CV is deemed seaworthy, then a sail
needs to be constructed.
To summarise, CV does not seem to be capitalising on the major advantages it
holds as a technique over other outcome methodologies. Overall, it is unclear
why and how a decision maker could use existing CV studies in resource allo-
cation decision-making. This failure to capitalise on the potential advantages of
CV by researchers could suggest that training in the technique is inadequate, the
technique is fundamentally flawed, the costs of doing CV appropriately are
astronomical, or simply that there are inadequate guidelines available to guide
researchers. The detachment between the doers and users of this research may
also mean that interested individuals do the studies for reasons of personal
interest rather than with a policy use in mind. It is quite likely that the answer
contains elements of all these arguments. However, these authors would not
suggest that the technique is fundamentally flawed; rather, it has not been
appropriately developed and applied in health economics.
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What sort of sail?
If the foundations of CV are seaworthy, decisions about the construction of CV,
or to use our metaphor the construction of the sail, need to be made. Histori-
cally, the key specifications have focused on scenario development and pre-
sentation, payment vehicle, respondent type, the incorporation of risk or
uncertainty, the time period over which WTP/WTA is estimated and the mode of
administration (Smith, 2003). In order to see what the specifications of the sail
should be, it is important to reflect back to see if, over time, a consensus has
been reached on any of these design aspects, whether there has been any con-
vergence towards a common agreed standard, as has been the case in other areas
of economic evaluation (NICE, 2004). Using the CV database used in previous
reviews of CV (see Olsen and Smith (2001), Smith (2003) and Sach et al. (2007)
for details) it is possible to address this question by looking at a few examples.
To know if the methodology used in CV studies has improved, one would
need a standard against which to judge. Within health economics, there has been
no formal guidelines established or validated, hence many studies claim to have
followed guidelines established within environmental economics, although very
much in an ad hoc fashion. Assuming this is acceptable for the moment, we can
illustrate change over time with reference to the National Oceanographic and
Atmospheric Administration (NOAA) guidelines (Arrow et al., 1993). Taking an
example using question-elicitation format first, the NOAA Panel recommended
that dichotomous-choice questions should be used in preference to open-ended
questions, as the latter are ‘biased, erratic and unreliable’ (Arrow et al., 1993).
The dichotomous-choice format was developed to attempt to resolve three
problems that had been encountered in using the open, bidding, and payment-
card formats: low response rates; strategic bias; and starting point (for bidding
games) or range (for payment card approaches) bias. This format was argued to
have three advantages over other techniques: it more closely resembles consumer
choice in an actual market situation; no one respondent can unduly influence the
overall WTP value; and it avoids starting point (and range) bias since respon-
dents are only presented with one bid (Smith, 2000).
One would expect such a significant recommendation to spill over to the
conduct of CV studies in health care. Table 7 demonstrates that between 1990
and 1996, dichotomous-choice questions represented fewer than any other
single format, yet for the period from 1996 to 1999 this format represented
more studies than were undertaken with any other single format. However,
Table 7 also illustrates that the majority of studies (80% across the full period)
were still not undertaken using the dichotomous-choice format. In more recent
years, since 2000, the payment card and bidding approaches have, especially,
been more widely reported, and critical attention has only been paid to the use
of different question formats within health economics in the last few years (Frew
et al., 2003, Whynes et al., 2003, 2004).
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As a second example, the method of survey administration recommended by
the NOAA Panel is that of face-to-face interviews. Smith (2003) reported that
41 studies (37%) collected data from face-to-face interview. Of the remaining
70 (63%) who did not undertake face-to-face interview, 12 (11%) used tele-
phone interview, 23 (21%) used postal self-administration and 29 (26%), other
self-administration. The technique was not available for six studies. Of the
154 studies published subsequently, the corresponding figures for studies
collecting data from face-to-face interviews, telephone, postal, and other
self-administration were 45% (70/154), 16% (25/154), 14% (21/154) and 15%
(23/154), with the technique not being available in 10% (15/154) of cases. This
would seem to indicate some improvement – there are more studies using face-
to-face and telephone interview, and less using postal or other self-complete
forms of administration, which should improve the quality of studies in this
latter period. There is, therefore, some hope, but the degree of change has
appeared non-universal across different aspects of design, perhaps indicative of
a lack of coordination or direction.
Of course, it may not be appropriate or desirable to apply the NOAA
guidelines, which were developed within a very specific context – valuing
Table 7. Questionnaire format over time
Year Open Bidding
Payment
card
Dichotomous-
choice single
Dichotomous-
choice double
Not
available
Multiple
format Total
1985 1 0 1 0 0 0 0 2
1986 0 0 0 0 0 0 1 1
1987 1 0 0 0 0 1 0 2
1988 0 0 2 0 0 1 0 3
1989 0 0 0 0 0 0 0 0
1990 0 1 1 0 1 0 0 3
1991 1 1 0 1 0 0 1 4
1992 1 0 1 0 0 1 0 3
1993 0 1 1 1 0 1 0 4
1994 1 1 2 1 0 2 2 9
1995 2 0 1 0 0 0 2 5
1996 1 2 1 2 0 0 1 7
1997 1 2 2 5 0 0 1 11
1998 1 5 4 4 2 0 2 18
1999 1 1 1 0 0 0 4 7
2000 2 4 6 0 1 5 5 23
2001 5 2 6 1 2 5 4 25
2002 3 2 9 3 3 7 4 31
2003 7 4 7 3 1 3 7 32
2004 3 10 6 8 3 2 5 37
2005 3 7 6 5 7 6 4 38
Total 34 43 57 34 20 34 43 265
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environmental damage caused by pollution for use in legal settlement. By its
very nature, environmental economics is mostly concerned with ‘non-use’
valuation of unfamiliar commodities, such as wildlife, areas of natural beauty or
air quality, and irreversible effects. In contrast, CV surveys in health care are
valuing a ‘good’ that is generally more familiar, the context (health system) is
familiar, the good (usually) providing direct ‘use-value’, and the good itself being
of a private (i.e. rival and excludable, and therefore tradable) rather than public
nature. Thus, for instance, there may be very justifiable reasons why health
economics may not wish to adopt NOAA recommendations for elicitation
formats, given the differences in what is being valued (Smith, 2006). However,
the critical issue is that there is no systematic exploration of this justification, or
application of alternative, health-specific, guidelines adopted in health eco-
nomics. As with other economic methodologies, there is a need for readily
identifiable criteria by which the quality of CV studies may be judged.
At the most fundamental level, this has meant that CV studies are not cur-
rently comparable, as health-specific CV studies lack agreement and adherence
to a specific design choice for each dimension (including, inter alia, how to
develop CV studies appropriately, what and how information should be pro-
vided in the scenario, elicitation format, respondent type, payment vehicle, time
frame for valuation, partiality, administration mode, and how risk and uncer-
tainty should be incorporated). The result of this is an inability to compare
across CV studies because they use incomparable methods on two or more
dimensions. This leads to an inability to look at the existing CV literature to try
to establish the impact of different design choices, as it is not clear which design
choice may have impacted the result across studies, even for studies of the same
or similar interventions, as they are intrinsically confounded. It therefore seems
critical that more systematic work be undertaken in order to consider how key
dimensions should be handled in these studies, and thus enable us to craft a sail
that is ready to drive the ship.
Setting sail: which direction?
This paper has thus far argued that applications of CV have failed to deliver on
the theoretical advantage of the technique, which, at least in part, has reflected
the absence of agreed guidelines in health economics about how to conduct CV
studies. The consequence has been a methods-policy gap where the technique
has had limited influence in decision-making processes. If the further pursuit of
CV is seen as a worthy cause then there is some work needed to make CV useful.
In this section, we make some tentative suggestions as to some ways forward,
and whilst readers may disagree with the detail, the key point being made is the
need to make some decisions on where to set our sail, otherwise the direction of
travel will never be determined and the good ship CV will continue to drift
about, not really being of any use to anyone.
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Box 1. Checklist of what should be reported in published CV studies
CV development and context
> Country where the CV survey has been conducted and health care
financing details
> Focus – methodological or policy
> Specificity of questionnaire (part of wider survey)
> Details of other measures of QoL incorporated
> Scenario development
> Welfare measure (WTP or WTA)
CV scenario description
> Intervention(s)
> Partiality (single good or close substitutes)
> Outcomes (health status, probability and time)
> Non-outcomes (information, care, other)
> Payment vehicle
> Presentation of uncertainty/risk
> Survey period
> Time period for WTP
> Question/elicitation format
CV reporting and results
> Method of data collection
> Type of respondent
> Sample size
> Response rate
> Type of outcomes incorporated (Use, option or externality value)
> Duration of interview/length of questionnaire
> WTP values (results of the studies)
> Transformation of values from one context/time to another
> Price year
> Currency
> Cost of intervention
> Cost–benefit ratio
> Time period used in analysis
CV validity and reliability
> Tests for bias – order effect, starting point, range, interviewer, strategic
> Statistical analysis performed
> Assessment of zero/high bids
> Distributional issues considere
J Income assessed
J Income adjustment
> Validity tests
> Reliability tests
104 R I C H A R D D . S M I T H A N D T R A C E Y H . S A C H
For this, there has to be a common standard in the reporting of CV studies in
the published peer-reviewed literature. For example, Sach et al. (2007) found
important design details missing in CV studies of pharmaceutical interventions
published since 2000. Here, 25% failed to report the elicitation method used
and 23% failed to report the price year. Both of these details are required in
order to interpret and compare the results in a useful manner. An obvious and
easily implemented solution to this problem would be the adoption by health
economists and journal editors of an agreed checklist, listing what details should
be included in published CV studies. Box 1 suggests what such a checklist might
include, covering all aspects from development, design and results, through to
tests of reliability or validity undertaken (see also Yeung and Smith (2006)).
Given the issues highlighted in this paper, we suggest that guidelines need to be
produced in a coordinated manner that can be used by authors, reviewers and
policy makers alike, which should also include guidance concerning how to deviate
from the guidelines appropriately when undertaking methodological work. For
instance, isolating the change of interest, rather than confounding the issue with
multiple simultaneous changes. The importance of guidelines is clearly demon-
strated by looking at the application of CV in the environmental and transport
safety literature where NOAAwas so influential in shaping the development of the
technique, and the production of government guidelines for CV conduct in these
areas. Given the methodological uncertainties that remain in CV as applied to
health care, any guidelines developed need to be formed on the basis of some
consensus so that they are adhered to. The simplest approach might, in the first
instance, be to adapt the NOAA guidelines in health (outlined in brief in Box 2).
Importantly, however, there has been little consideration of whether the
methodology found in the application of CV in the environmental or transport
safety literature is directly translatable to health care and, if so, whether this is
even desirable (in most areas of the application of economics to health care, we
consider ‘health’ to be sufficiently ‘different’ to warrant specific adaptations to
theory and/or practice (Mooney, 1986, 1994), so why not here?). It would seem
sensible for research to first address the applicability of CV guidelines in other
branches of economics before developing and coordinating work to create new
ones in health. The main point to note is that there is no point tinkering if there
is no common purpose. A coordinated research effort, that ensures research is
reported appropriately and isolates the one aspect being varied, would go some
way towards making CV useful to policy.
Others might fundamentally disagree with using NOAA as a starting point on
the basis that health is sufficiently different from the environment and that it
makes no logical sense to start from that point. Such an argument could be seen
as quite persuasive in terms of the misspecification issue raised earlier in the
paper, for instance. Because health CV values extend beyond non-use and
irreversible decisions, there could be a recommendation that the default
assumption be that all elements of value are of importance such that researchers
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Box 2. NOAA guidelines (adapted from Arrow et al., 1993)
Development:
> Pilot work and pretesting should be conducted and described
Design choices:
> Willingness to pay format should be used
> Probability sampling
> Define the budget constraint
> State the payment vehicle
> Face-to-face interviews or telephone interviews
> Dichotomous-choice question format, with a no answer option such
respondents should be asked to explain their choice
> Adequate information about that which is being valued should be
included (this should include the change in health state, the probability
and duration)
> Respondents need to be reminded of other commodities directly and that
their expenditure on other private goods will be reduced as a result of the
WTP question
> The survey should be employed across different time points with
independent samples to test for time trends
> The survey should include questions about other factors which might
explain responses, for instance:
J Income
J Prior knowledge of the issue
J Prior interest in the issue
J Attitudes towards health
J Attitudes toward the NHS
J Relevance of issue
J Understanding of the task
J Belief in the scenarios
J Ability/willingness to perform the task
> Tests of interviewer effects should be incorporated
Reporting, should include clear details on:
> The population sampled
> The sampling frame used
> The sample size
> The overall sample non-response rate, detailing refusals and item non-
response
> The paper should reproduce the exact wording and sequence of the
questionnaire and of other communications to respondents so that design
choices are clear to see
> Data from the study should be retained and made available to those
interested
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must explicitly consider the relevance of use, externality and/or option value in
their design and discuss how this issue was tackled. Similarly, research around
elicitation format in health by no means necessarily supports the use of the
dichotomous-choice questions over other formats and, therefore, health econ-
omists may wish to agree on the use of payment scales or another format as their
preferred base case option. The key point being made here is that this requires
systematic discussion and application.
Clearly, guidelines will never produce a ‘perfect’ CV study. By their very
nature, CV studies are flawed representations of the world. Their purpose is not
to achieve perfection but rather to provide a structure to guide movement
toward obtaining more accurate values, a belief presumably driving all forms of
research into aspects of the valuation exercise, such as embedding effects,
payment vehicles, or scenario specification. Indeed, it is perhaps somewhat
ironic that not only despite, but perhaps because, of such high-profile guidelines,
and the wealth of research undertaken into CV surveys in general, there is not
greater consistency in the conduct of CV surveys. However, this paper indicates
not only that CV studies in health care have performed poorly in the con-
struction, specification and presentation of the contingent market, but also that
there has been little, if any, improvement in this respect over the last 20 years.
Who will captain the ship?
Of course, setting direction and staying on course requires a captain. The paper
has thus far considered the what-needs-to-be-done question, but we also need to
consider who should, or could, captain the ship.
Health economists could choose to be proactive and coordinate themselves so
as to develop the technique themselves or in collaboration with researchers from
other disciplines. Alternatively, health economists could wait for provocation to
do something. This might come in the form of a major health accident, akin to
the impetus for the NOAA recommendations, or rather more likely as a policy
agenda that forces change. From a policy point of view, if health economists
were to focus narrowly on evaluating the value for money of curative technol-
ogies that only have health benefits, then arguably CV might be unnecessary,
other than in helping determine the overall allocation of resources to health
from the treasury perhaps. In reality, of course even clinical interventions often
Quality assessment:
> High response rate
> Responsiveness to the scale of the good or service being valued
> Understanding of the task by respondents
> Belief in the scenario
> Yes or no votes should be explained in terms of cost and/or value of the
good or service.
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have spillover effects onto family carers or children in terms of educational
benefits for example. Such benefits are not captured in traditional cost per
QALY analysis, which could be justified by organisations such as NICE in the
UK, on the grounds that an NHS and social services perspective is taken.
However, in 2005 the remit of NICE expanded to incorporate public health, as
it took on the functions of the Health Development Agency, an area where the
costs and benefits very clearly extend beyond the health care arena and have
consequently challenged standard economic evaluation methods.
To deal with this, NICE has extended the scope of costs captured in economic
evaluations and whilst benefits remain assessed by QALYs, a cost-consequent
approach has also been adopted to take account of the wider benefits where
possible (Drummond et al., 2007). Such an approach does not seem ideal since
potentially non-health benefits could be attached less weight than the health
effects, biasing decisions towards those with larger health gains. Potentially, this
agenda could provide an impetus to develop CV methods in health care. This being
the case then NICE might be an appropriate lead. However, the CVapproach then
risks not being captained anywhere, except to the bottom of the sea perhaps,
because certain elements of the health economics community may not approve
of the technique. This paper has shown that on current evidence such an opinion
of the technique might actually be well founded. However, it is one thing to
demonstrate that a technique has failed in the past but another to argue that it
could never work in the future, which is what concerns us in this paper.
To conclude, it seems to us that now would seem an appropriate time to take
stock of the history of CV in health economics, in part because the ad hoc
application of CV can no longer be ignored and in part because new opportunities
such as the public health economics agenda may renew the potential importance of
the technique. This paper has attempted to be provocative in the hope of stimu-
lating response and debate about the future of CV because the status quo seems
clearly inadequate, and as a profession it is arguably our responsibility to debate
whether this means it should be put in to port and never sailed again, or is given
the ability to set sail and travel to new and exciting places!
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